1 The EIC Accelerator Project
EIC Accelerator Program Overview
The EIC Accelerator, part of the European Innovation Council (EIC), is a funding initiative designed to support innovative startups and SMEs with breakthrough technologies. This program addresses the specific challenges faced by deep-tech ventures, providing them with both financial resources and strategic guidance to scale their operations. The EIC Accelerator offers a blended finance model, combining grants and equity investments, allowing companies to leverage public funding to attract additional private investments.
Funding Structure
The EIC Accelerator provides funding through two components: grants and equity.
Purpose of the EIC Accelerator
The EIC Accelerator plays a pivotal role in the European deep-tech and startup ecosystem. Its primary purpose is to bridge the funding gap that many innovative companies face during their growth phases. By offering a combination of grants and equity, the EIC Accelerator enables startups to pursue ambitious projects that can drive economic growth and technological advancement within Europe.
Additionally, the program aims to stimulate collaboration between public and private sectors, encouraging investors to engage with high-potential startups. This dual approach helps de-risk investments for private entities, making it more attractive for them to contribute to the commercialization of groundbreaking technologies.
Role in Scaling Companies
The EIC Accelerator not only provides financial backing but also equips companies with essential resources and support. Successful applicants benefit from advisory services, including mentorship from industry experts, access to networks, and guidance on navigating regulatory challenges. This holistic approach ensures that companies are not only funded but also strategically positioned for success in competitive markets.
By facilitating access to additional funding sources and resources, the EIC Accelerator significantly enhances a company's ability to scale operations, develop innovative solutions, and ultimately achieve market penetration.
EIC Accelerator Winner: NEOS NEW BORN SOLUTIONS SL
Project Acronym: NEOSONICS
Website: newborn.solutions
Country: Spain
Submission Date: March 23, 2022
Project Description
NEOS NEW BORN SOLUTIONS SL has developed NEOSONICS, a groundbreaking medical device designed for the non-invasive detection and monitoring of infant meningitis. Meningitis, a severe infection of the protective membranes covering the brain and spinal cord, can lead to serious complications, particularly in infants. Early detection and monitoring are crucial for improving outcomes and reducing mortality rates.
Technology Basics and Background
The NEOSONICS device utilizes advanced ultrasound technology to detect signs of meningitis in infants without the need for invasive procedures such as lumbar punctures. This non-invasive approach is particularly beneficial for infants, who are vulnerable and require gentle handling during medical assessments.
The technology behind NEOSONICS is rooted in sophisticated signal processing algorithms that analyze ultrasound wave patterns and identify abnormal signals indicative of meningitis. By employing a user-friendly interface, healthcare providers can quickly obtain results, enabling timely medical intervention.
The development of NEOSONICS is positioned within a broader context of increasing healthcare innovation aimed at enhancing patient outcomes while minimizing discomfort and risk. The EIC Accelerator's support allows NEOS NEW BORN SOLUTIONS SL to further refine their technology, conduct clinical trials, and promote adoption within healthcare systems across Europe.
By securing funding through the EIC Accelerator, NEOS NEW BORN SOLUTIONS SL is poised to make a significant impact in pediatric healthcare, addressing a critical need for effective, non-invasive diagnostic tools that can save lives.
2 The Funding Rounds
Financing Raised and Funding Rounds
Neos New Born Solutions SL, based in Barcelona, Spain, is a medical device and software startup focused on non-invasive screening, diagnosis, and monitoring of infections in serous fluids—most notably for infant meningitis. Since winning the EIC Accelerator funding following their Step 2 proposal submission on March 23, 2022, Neos New Born Solutions has received recognition and support from several major institutions including the European Innovation Council (EIC), EIT Health, MIT support programs, Philips Healthworks, The Bill & Melinda Gates Foundation, AECID (Spanish Agency for International Development Cooperation), as well as various national and international bodies.
EIC Accelerator Funding
- Timing: The company’s successful Step 3 interview resulting in the award occurred after March 23, 2022.
- Amount: While specific figures from this round are not detailed in public domain sources for Neos New Born Solutions SL post-March 2022 cut-off date:
- Standard EIC Accelerator grants typically range up to €2.5 million per project in grant funding (non-dilutive) with optional equity investments up to €15 million. It is highly likely that Neos New Born Solutions SL received a package within this standard structure.
Other Notable Grants & Support
- In addition to the EIC Accelerator grant/equity package:
- The company has secured backing or recognition from MIT’s innovation initiatives.
- Philips Healthworks and The Bill & Melinda Gates Foundation have supported or partnered with the firm.
- Additional funds or project-specific grants may have been provided by Spanish national agencies such as AECID.
- No publicly disclosed record exists of large private venture capital rounds beyond these institutional supports since March 2022.
Investor Information
The main investors known are public innovation bodies rather than traditional venture capitalists: - European Innovation Council (EIC)
- MIT innovation programs
- Philips Healthworks
- Bill & Melinda Gates Foundation
- AECID
There is no evidence of other private VC investors leading rounds into Neos New Born Solutions SL since their EIC win.
Funding Rounds: Timing & Amounts
After securing the prestigious EIC Accelerator award around Spring/Summer 2022:
- No subsequent fundraising rounds—such as Series A/B/C—have been publicly announced for Neos New Born Solutions SL by April 30th, 2025.
- There are no disclosed details regarding further equity injections or convertible notes post-EIC round.
If future follow-on investment occurs via new private lead investor(s) or further EU institutional tranches it would be expected per standard sector practice; however there is no public evidence available at this time.
Company Valuation
No explicit valuation figure has been published for Neos New Born Solutions SL following their most recent fundraising activities. In general terms:
Exit Events: IPOs/Buyouts/Acquisitions
As of April 30th, 2025:
The company remains an independent entity headquartered at Barcelona Science Park—with ongoing platform development targeting global medical technology markets.
Summary Table
| Event | Status / Details |
|---|---|
| Last Major Funding | EIC Accelerator Grant+Equity Package (~Spring/Summer '22) |
| Investors | Public/EU institutions + global health orgs |
| Subsequent Rounds | None publicly announced |
| Valuation | Not disclosed |
| Exits/IPOs/Acquisitions | None reported |
Sources
Neos Newborn Solutions profile – Listen2Future Parc Científic de Barcelona – Company Profile3 The Press Releases
NEOS New Born Solutions SL: A Leader in Non-Invasive Infection Screening
NEOS New Born Solutions SL, based in Spain, is a medical device and software startup that has gained significant recognition for its innovative approach to non-invasive screening, diagnosis, and monitoring of infections in serous body fluids. Since winning the EIC Accelerator funding on March 23, 2022, the company has continued to advance its technology and expand its applications.
Technology and Applications
NEOS New Born Solutions SL utilizes high-resolution ultrasounds, unique coupling materials, and machine learning algorithms to automate the count of white blood cells in serous fluids. This technology serves as a diagnostic marker for infections and inflammatory diseases. Initially focusing on infant meningitis, the company has expanded its platform to address other conditions such as peritoneal dialysis-related peritonitis and intraocular inflammation (uveitis) .
Partnerships and Recognition
The company has been supported by several prestigious institutions, including MIT, Philips Healthworks, EIC Accelerator, EIT Health, The Bill & Melinda Gates Foundation, and AECID. These partnerships highlight the potential impact of NEOS New Born Solutions SL's technology in democratizing access to accurate and affordable diagnostic tools .
Team and Operations
As of recent updates, the team consists of 12 full-time employees with diverse nationalities and a strong academic background, including five PhDs and two PhD candidates. The company operates from the Barcelona Science Park, which provides a conducive environment for research and development .
Press Releases and Updates
While specific press releases from NEOS New Born Solutions SL are not readily available, the company's involvement in evaluating technologies such as PMUT (Piezoelectric Micromachined Ultrasonic Transducers) indicates ongoing efforts to enhance their non-invasive screening capabilities . Updates on their progress and achievements can be expected through their social media channels and official website.
Conclusion
Since receiving the EIC Accelerator funding, NEOS New Born Solutions SL has continued to push the boundaries of non-invasive infection screening. Their innovative approach and strategic partnerships position them as leaders in the medical technology sector, particularly in addressing critical conditions such as infant meningitis.
Sources: - Kriba
4 The Technology Advancements
NEOS New Born Solutions SL: Post-EIC Accelerator Funding ProgressSince receiving EIC Accelerator funding in March 2022, NEOS New Born Solutions SL (operating as Kriba) has focused on advancing its non-invasive diagnostic platform for serous fluid infections. While specific post-2022 milestones are not explicitly detailed in publicly available documents, the company’s core advancements and activities can be summarized as follows:
Core Technology and Current Capabilities
The company’s flagship technology utilizes high-resolution ultrasound, proprietary coupling materials, and machine learning algorithms to automate white blood cell counts in serous fluids within seconds. This approach targets infant meningitis initially but has expanded to peritoneal dialysis-related peritonitis and uveitis. Their device aims to replace invasive lumbar punctures for infection screening, emphasizing rapidity and cost-efficiency.Post-Funding Advancements
While direct updates post-2022 are limited in public records, the company likely accelerated efforts to validate its platform across broader applications. The EIC Accelerator funding specifically aimed to evaluate PMUT (Piezoelectric Micromachined Ultrasound Transducer) technology’s potential for enhancing their diagnostic accuracy, suggesting ongoing integration of advanced ultrasound components. Additionally, their participation in EU projects underscores a focus on collaborative innovation, though no new patents or peer-reviewed studies directly linked to recent developments were identified.Market Demonstration and Clinical Validation
NEOS references patient follow-up capabilities through cellularity monitoring in clinical documentation, indicating deployment in real-world settings. However, explicit details about recent pilots or trials remain undisclosed. The Barcelona Science Park location provides access to clinical partners for testing, though no trial registries or results post-2022 were found.Intellectual Property and Publications
Publicly available data does not specify new patent filings or scientific publications since 2022. Their earlier work emphasizes machine learning-driven automation of diagnostics, which may have evolved further with EIC-funded R&D efforts related to PMUT optimization. Collaborations with institutions like MIT and Philips Healthworks suggest sustained innovation but lack recent disclosures.Sources
- Neos Newborn Solutions SL - Listen2Future
- CIP_UNITED_Meningitis PDF
- Neos New Born Solutions - Parc Científic de Barcelona
- Kriba.ai
5 The Partnerships and Customers
NEOS New Born Solutions SL: Strategic Partnerships and Market PositioningNEOS New Born Solutions SL (Kriba), a Barcelona-based medical technology startup, has leveraged its EIC Accelerator funding to advance non-invasive diagnostic solutions for serous fluid infections. While specific recent customer names are not publicly disclosed, the company’s collaborations and strategic focus areas provide insights into its market positioning and technological advancements.
Key Partnerships and Collaborations
- Listen2Future Consortium: NEOS participates in this €30 million EU project alongside 27 partners, including Infineon Technologies Austria AG, to evaluate piezoelectric micromachined ultrasound transducers (PMUT) for enhancing its diagnostic platform.
- Institutional Supporters: The company has secured backing from MIT, Philips Healthworks, EIT Health, the Bill & Melinda Gates Foundation, and AECID for R&D and global health initiatives.
Technological Advancements Through Partnerships
The Listen2Future project focuses on integrating PMUT technology into NEOS’s proprietary ultrasound-based devices. This collaboration aims to improve the automation of white blood cell counting in serous fluids using machine learning algorithms, potentially expanding applications to peritoneal dialysis-related peritonitis and uveitis monitoring.Market Positioning
By aligning with multinational consortia and healthcare institutions, NEOS is positioned as a leader in non-invasive infection screening. Its focus on infant meningitis—a critical global health challenge—enhances its credibility in pediatric care innovation. The diversified application of its platform across multiple medical conditions supports scalability in both clinical and domiciliary settings.Scaling Impact
The integration of advanced ultrasound technologies through partnerships like Listen2Future could streamline regulatory approvals (e.g., CE marking) by demonstrating improved accuracy over traditional invasive methods. Additionally, institutional support provides access to cross-continental clinical networks for pilot testing and market entry.Sources
- Neos New Born Solutions SL - Parc Científic de Barcelona
- Listen2Future Consortium - Neos Newborn Solutions
- Kriba.ai - Non-invasive Infection Screening
6 The Hiring and Company Growth
Overview of NEOS NEW BORN SOLUTIONS SL
NEOS NEW BORN SOLUTIONS SL, a medical device and software startup located at the Barcelona Science Park in Spain, has been making significant strides in healthcare technology since receiving the EIC Accelerator funding in March 2022. Here is an overview of the company's current status and growth trajectory:
Current Headcount and Team Size
As of the latest available data, NEOS NEW BORN SOLUTIONS SL has a team of approximately 12 full-time employees with diverse backgrounds, including five PhDs and two PhD candidates.
Hiring and Team Growth
There is no specific information on whether the company is currently hiring, but given their growth trajectory and involvement in multiple projects, it is likely they are expanding their team to meet the demands of their innovative medical device development. The company benefits from the diverse skills and expertise of its team members, which are crucial for their mission to democratize access to accurate diagnostic tools for infections in serous fluids.
Growth Since EIC Funding
Since receiving the EIC Accelerator funding in March 2022, NEOS NEW BORN SOLUTIONS SL has continued to advance its non-invasive screening and monitoring technology for infections in serous fluids. The funding likely played a significant role in accelerating their product development and market reach.
Key Positions and Recent Hires
While specific details on recent hires are not available, the company's focus on technology and innovation suggests that they would be hiring in roles related to medical device development, software engineering, and research. These roles would be crucial in helping them scale and meet the growing demand for their products in areas like infant meningitis and peritoneal dialysis-related infections.
Impact of New Team Members
New team members will be essential in helping NEOS NEW BORN SOLUTIONS SL scale by bringing in fresh perspectives and expertise. Their contributions will likely enhance the company's ability to develop more advanced diagnostic tools and expand into new markets, ultimately improving healthcare outcomes globally.
Management and Founding Team Changes
There is no publicly available information on significant changes in management or the founding team. However, the company's recognition and support from prestigious institutions indicate a stable and effective leadership structure.
Sources
- Neos New Born Solutions, SL - Parc Científic de Barcelona
- NEOS NEW BORN SOLUTIONS SL. Company Profile
- neos new born solutions, sl - Barcelona & Catalonia STARTUP HUB
- ️Neos New Born Solutions Sl
- Neos Newborn Solutions SL
- Kriba
7 The Media Features and Publications
Media Features and Publications NEOS NEW BORN SOLUTIONS SL (operating as Kriba) has been featured in EU-funded research portals and technology innovation platforms. The CORDIS EU Research Results highlighted their NEOSONICS project, emphasizing its non-invasive approach to infant meningitis screening using high-resolution ultrasound and machine learning. The Listen2Future Consortium detailed their role in evaluating PMUT technology for infection monitoring, underscoring their collaboration with international institutions like MIT, Philips Healthworks, and the Bill & Melinda Gates Foundation.Podcasts and Interviews
No publicly available podcasts or direct interviews with the NEOS team were identified in the provided sources. However, their work is frequently cited in EU project reports and medical innovation summaries.
Conferences and Fairs
The company actively participates in EU-funded initiatives, including the NEOSONICS Horizon 2020 project, which involved clinical validation efforts post-Phase 1 feasibility studies. They also collaborate with the Listen2Future Consortium, focusing on PMUT (Piezoelectric Micromachined Ultrasound Transducers) applications for healthcare diagnostics. While specific conferences are not named, their involvement in large-scale consortia suggests regular presentations at medical technology expositions.
Event Involvement
NEOS has secured recognition through multiple high-profile accelerators:
- EIC Accelerator: Received Phase 1 funding (2019) followed by SME Instrument Phase 2 support to advance clinical trials.
- EIT Health: Supported early-stage development of their diagnostic platform.
- MIT Solver Team: Recognized for innovative healthcare solutions targeting neonatal care.
Sources
CORDIS: Ultrasound device for infant meningitis detection Listen2Future: Neos Newborn Solutions SL CORDIS: NEOSONICS Project ReportDo you need EIC Accelerator support?
Here is a list of the key service options for the EIC Accelerator:
Full Writing Service
All proposal sections are written by Stephan Segler, PhD.
Advisory Service
You write in-house but receive 1-on-1 support, templates, instructions, and reviews of all documents.
AI Writer & Training
A high-quality AI writer for EIC Accelerator Step 1 and a comprehensive Training program for Steps 1 and 2 including all templates and instructions.